Squamous Cell Carcinoma Antigen: Clinical Application and Research Status

Zhu, Huange

doi:10.3390/diagnostics12051065

Cited by 23 publications

(24 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…But gender differences have to be considered, as low levels of SCCA-IgM after transarterial embolization indicate more prolonged survival in males and shorter in females ( 213 ). SCCA and SCCA-IgM show moderate diagnostic accuracy in several meta-analyses ( 214 – 216 ). Combination with AFP increases prognostic value significantly ( 214 ).…”

Section: Promising New Biomarkers For Clinical Applicationmentioning

confidence: 99%

HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice

et al. 2022

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common and deadly tumors worldwide. Management of HCC depends on reliable biomarkers for screening, diagnosis, and monitoring of the disease, as well as predicting response towards therapy and safety. To date, imaging has been the established standard technique in the diagnosis and follow-up of HCC. However, imaging techniques have their limitations, especially in the early detection of HCC. Therefore, there is an urgent need for reliable, non/minimal invasive biomarkers. To date, alpha-fetoprotein (AFP) is the only serum biomarker used in clinical practice for the management of HCC. However, AFP is of relatively rather low quality in terms of specificity and sensitivity. Liquid biopsies as a source for biomarkers have become the focus of clinical research. Our review highlights alternative biomarkers derived from liquid biopsies, including circulating tumor cells, proteins, circulating nucleic acids, and exosomes, and their potential for clinical application. Using defined combinations of different biomarkers will open new perspectives for diagnosing, treating, and monitoring HCC.

show abstract

Section: Promising New Biomarkers For Clinical Applicationmentioning

confidence: 99%

HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice

et al. 2022

View full text Add to dashboard Cite

show abstract

“…SCCA, also known as squamous cell carcinoma antigen, has emerged as a prominent tumor marker. It has garnered significant attention because of its multifaceted biological functions and profound implications in both normal physiological processes and pathological conditions [9]. Xu et al.…”

Section: Discussionmentioning

confidence: 99%

Clinical utility of six serum tumor markers for the diagnosis of lung cancer

Yang,

Chang,

Wang

et al. 2023

iLABMED

View full text Add to dashboard Cite

BackgroundWith the increasing prevalence of lung cancer, it has become imperative to identify reliable biomarkers that can aid in early detection and prognosis assessment. Therefore, we sought to investigate the potential utility of six serum tumor markers as diagnostic and prognostic tools for lung cancer patients. By analyzing a large cohort of patients with different stages and subtypes of lung cancer, we hoped to shed light on the predictive value and accuracy of each marker individually, as well as their combined performance. This study should not only provide valuable insights into the biology and pathogenesis of lung cancer but also pave the way for personalized treatment strategies based on individual patient profiles.MethodsThe serum levels of the tumor markers progastrin‐releasing peptide (ProGRP), carcinoembryonic antigen (CEA), neuron‐specific enolase (NSE), cytokeratin 19 fragment (CYFRA21‐1), carbohydrate antigen 19‐9 (CA19‐9) and squamous cell carcinoma antigen (SCCA) were meticulously assessed in a cohort comprising 324 individuals diagnosed with lung cancer and an additional 51 patients with benign lung disease. The measurements were conducted using cutting‐edge techniques such as ELISA, electrochemical luminescence, and chemiluminescence methods. Differences between groups and the impact of these markers on lung cancer diagnosis were analyzed.ResultsThe serum levels of ProGRP, NSE, and CEA were significantly higher in lung cancer patients than in patients with benign lung disease (p < 0.01). NSE had the highest sensitivity for squamous cell carcinomas (SC), while CEA had the highest sensitivity for adenocarcinomas (AC). ProGRP and NSE had higher sensitivities than other markers for small cell carcinomas (SCC). Combining the six tumor markers resulted in higher sensitivities for SC (70.6%), AC (77.4%), and SCC (80%) compared with any single test. Receiver operator characteristic analysis showed that ProGRP and NSE had a greater area under the curve (AUC) in SCC (0.886 and 0.775) than SC and AC, while CEA had a higher AUC in AC (0.716), and NSE had a higher AUC than other markers in SC (0.719).ConclusionsProGRP and NSE are effective serum tumor markers for SCC, whereas CEA and NSE may aid in the diagnosis of AC and SC. Combining the detection of ProGRP, NSE, CYFRA21‐1, CEA, and SCCA significantly improves sensitivity when diagnosing lung cancer.

show abstract

“…In addition, hematological but not in ammatory indicator SCC-Ag shows the independent predictive value for DFS. This may be because, on the one hand, SCC-Ag is associated with the expression of E-cadherin and β-catenin, which trigger epithelial-mesenchymal transition and promote invasion and metastasis; on the other hand, SCC-Ag secreted by tumor cells in lymph nodes and circulating tumor cells is also more easily detected in the blood stream [27]. Moreover, by further calculating the cut-off value, we found that cervical cancer patients with SCC-Ag < 1.47ng/ml had a lower risk of recurrence and metastasis, similar to the results of Salvatici[28], which may have some reference value for further clinical strati cation.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Assessment of Postoperative Recurrence and Survival in Patients with Cervical Cancer: Nomograms

Jia

Qian

et al. 2023

Preprint

View full text Add to dashboard Cite

Background To investigate the value of nomograms based on clinical parameters, inflammatory indicators, intravoxel incoherent motion diffusion weighted imaging (IVIM-DWI) and MRI-derived radiomics in predicting recurrence-free survival (RFS), disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS) in cervical cancer patients after surgery.Methods A retrospective analysis of 181 cervical cancer patients operated at our hospital between January 2015 and January 2021 with continuous follow-up was completed. The parameters of IVIM-DWI and radiomics were measured, analyzed and screened. The logistic regression with LASSO regularization was used to calculate radiomics score (Rad-score). Multivariate Cox regression analysis was used to construct nomogram models for predicting postoperative RFS, DFS, CSS and OS in cervical cancer patients, with internal and external validation.Results Clinical stage, parametrial infiltration, internal irradiation, D-value and Rad-score were independent prognostic factors for RFS; Squamous cell carcinoma antigen, internal irradiation, D-value, f-value and Rad-score were independent prognostic factors for DFS; Maximum tumor diameter, lymph node metastasis, platelets, D-value and Rad-score were independent prognostic factors for CSS; Lymph node metastasis, systemic inflammation response index, D-value and Rad-score were independent prognostic factors for OS. The AUCs of each model predicting RFS, DFS, CSS and OS at 1, 3 and 5 years were 0.985, 0.929, 0.910 and 0.833, 0.818, 0.816 and 0.832, 0.863, 0.891 and 0.804, 0.812, 0.870, respectively.Conclusions Nomograms based on clinical and imaging parameters showed high clinical value in predicting postoperative RFS, DFS, CSS and OS of cervical cancer patients and can be used as prognostic markers.

show abstract

Squamous Cell Carcinoma Antigen: Clinical Application and Research Status

Cited by 23 publications

References 92 publications

HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice

HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice

Clinical utility of six serum tumor markers for the diagnosis of lung cancer

Comprehensive Assessment of Postoperative Recurrence and Survival in Patients with Cervical Cancer: Nomograms

Contact Info

Product

Resources

About